Anthem Biosciences promoters confirm no encumbrance on shares in FY26
Anthem Biosciences Ltd promoter Ganesh Sambasivam declared that the promoter group did not encumber any shares during FY26. The filing, submitted to BSE and NSE under SEBI takeover regulations, lists nine group members. The declaration was signed in Bengaluru on April 06, 2026.
*this image is generated using AI for illustrative purposes only.
Anthem Biosciences Ltd promoter Ganesh Sambasivam confirmed that the promoter group did not create any encumbrance on shares held directly or indirectly during the financial year ended March 31, 2026. The declaration ensures that the shareholding remains free from charges such as pledges, which is critical for shareholder confidence regarding ownership stability.
The disclosure was submitted to BSE and NSE pursuant to Regulation 31(4) and 31(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. These regulations mandate periodic reporting to maintain transparency regarding the holding status of promoters and persons acting in concert.
Promoter Group Details
The filing identified Ganesh Sambasivam as the primary declarant on behalf of the promoter and promoter group. The confirmation covers all shares held by the group members throughout the specified financial year.
The following table lists the members of the promoter group as provided in the filing:
| SL. No. | Name of the members of Promoter Group |
|---|---|
| 1. | Aruna Ganesh |
| 2. | Krithika Ganesh |
| 3. | Sambasivam Hariharan |
| 4. | Sambasivam Mahesh |
| 5. | Suganthi Subramanian |
| 6. | Sasirekha |
| 7. | Herambaya Trust |
| 8. | Sumukhaya Trust |
| 9. | Cellf Therapeutics Private Limited |
The declaration was signed on April 06, 2026, in Bengaluru. A copy of the communication was forwarded to the Audit Committee of anthem biosciences for their records.
Historical Stock Returns for Anthem Biosciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.55% | +0.76% | +2.77% | +21.45% | +6.11% | +6.11% |
How will this clean shareholding status impact Anthem Biosciences' ability to raise future capital or secure debt?
Are there any strategic M&A or expansion plans on the horizon that might require the promoters to leverage their holdings?
How does this declaration influence investor sentiment regarding the company's governance standards ahead of the upcoming AGM?
17
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
